Revlimid boosts survival in myeloma patients post-transplant
admin 28th July 2017 Uncategorised 0Celgene has unveiled a meta-analysis of pooled data from three late-stage studies showing a significant overall survival benefit in patients newly diagnosed with multiple myeloma receiving Revlimid as maintenance therapy following autologous stem cell transplantation.
More: Revlimid boosts survival in myeloma patients post-transplant
Source: News